Composition for treating depression and application thereof

Abstract

The invention discloses a composition for treating depression and application of the composition. The composition for treating depression is prepared from the following components in parts by weight: 35 to 40 parts of ligustilide, 0.5 to 1.5 parts of atractydin and 0.1 to 1 part of alpha-cyperone. According to the invention, the active components in the Yueju pill, which are targeted to 5-HT1AR and 5-HTT, are compounded for the first time to prepare a new traditional Chinese medicine functional component composition, and in addition, the anti-depression effect of the active components is evaluated by establishing a reserpine mouse depression model, so that the anti-depression effect of the Yueju pill is improved. The result shows that the active component composition screened by the 5-HT1AR and 5-HTT targets can adjust the content of monoamine neurotransmitters in brain tissues in vivo to achieve the anti-depression effect, and in-vivo pharmacological experiments fully prove that the composition has the anti-depression effect.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and particularly relates to a composition for treating depression and its application. Background Art

[0002] Depression is an emotional disorder with abnormal central nervous system, and its main clinical feature is emotional regulation disorder. In recent years, the cumulative number of global depression patients has exceeded 350 million, and the lifetime prevalence rate is 3.4%. According to the statistics of the World Health Organization, depression will become the second largest disease in the world by 2030. The onset of depression is not only affected by biological and physiological factors, but also involves social living environment and other factors. It can occur simultaneously with other diseases, and has a high recurrence risk and suicide rate. Moreover, the onset of depression is gradually getting younger, and the number of adolescent depression patients is increasing continuously, which seriously endangers people's physical and mental health. At present, the treatment methods of depression still rely on traditional antidepressant drugs such as reuptake inhibitors and monoamine oxidase inhibitors. Although these drugs can provide certain relief for depressive symptoms, only 1 / 3 of the patients can show obvious improvement, and the onset latency of these drugs may last for several weeks or even months, and there are serious withdrawal effects. Therefore, it is urgent to develop more effective drugs for treating depression.

[0003] The etiology and pathogenesis of depression are complex. At present, the main pathogenesis of depression includes monoamine neurotransmitter hypothesis, inflammatory cytokine hypothesis, hypothalamic-pituitary-adrenal (HPA) axis hypothesis, brain-derived neurotrophic factor (BDNF) hypothesis, etc., but it is still not clear enough. There is currently a lack of effective treatment means for this disease and the course of the disease is long. Most patients need long-term or even lifelong treatment after diagnosis, causing serious mental and economic burdens to patients and their families. In recent years, with the continuous in-depth research on depression, four types of target-specific antidepressant drugs represented by monoamine oxidase inhibitors (MAOIs), tricyclic and tetracyclic antidepressants (TCAs), selective 5-HT reuptake inhibitors (SSRIs), and 5-HT and NE reuptake inhibitors (SNaRIs) have been developed, which have a certain effect on controlling the progression of depressive conditions. However, taking them for a long time has great side effects, is prone to drug dependence, and patients are prone to withdrawal reactions and the condition recurs after stopping the drug.

[0004] In traditional Chinese medicine theory, depression belongs to "Yu disease", mainly manifested as stagnation of liver qi, transformation of liver qi into fire, liver depression and spleen deficiency, deficiency of both the heart and spleen, and disharmony between the heart and kidney. Traditional Chinese medicine has the advantages of small toxic and side effects, multi-target synergy, and significant antidepressant effects, and is widely used in the improvement and treatment of depression. Modern clinical and pharmacological studies have shown that Yueju Pills have significant antidepressant effects. However, the traditional usage of Yueju Pills is to make water-pan pills and directly use the whole medicine, and its formula composition is complex and the core effective components are not clear. Therefore, it is particularly important to extract the key quality attributes of Yueju Pills, screen out the formula with clear effective components, optimize the preparation process, and obtain a composition with clear effective components and superior antidepressant effects.

[0005] In view of this, the present invention is specifically proposed. Summary of the Invention

[0006] The purpose of the present invention is to provide a composition for treating depression and its application. The composition for treating depression of the present invention can regulate the content of monoamine neurotransmitters in the brain tissue, and thus exert antidepressant effects.

[0007] In order to achieve the above object of the present invention, the following technical solutions are specifically adopted: The first aspect of the present invention provides a composition for treating depression, and the composition for treating depression comprises the following components in parts by weight: Ligustilide 35 - 40 parts, Atractylodin 0.5 - 1.5 parts, and α-Cyperone 0.1 - 1 part.

[0008] Preferably, the composition for treating depression comprises the following components in parts by weight: Ligustilide 37 - 39 parts, Atractylodin 0.8 - 1.2 parts, and α-Cyperone 0.2 - 0.5 parts.

[0009] The second aspect of the present invention provides an application of the above composition for treating depression in the preparation of a product for treating depression.

[0010] Preferably, the product is a drug or a health product.

[0011] The third aspect of the present invention provides a drug for treating depression, and the drug for treating depression comprises a therapeutically effective amount of the composition for treating depression.

[0012] Preferably, the drug for treating depression further comprises a pharmaceutically acceptable excipient.

[0013] Preferably, the dosage form of the drug for treating depression includes oral liquid, pill, powder, granule, tablet, capsule, and injection.

[0014] The fourth aspect of the present invention provides a health product for treating depression, and the health product for treating depression includes the composition for treating depression.

[0015] Preferably, the health product for treating depression further includes a pharmaceutically acceptable excipient.

[0016] Compared with the prior art, the beneficial effects of the present invention at least include: The present invention established a reserpine-induced mouse depression model to evaluate the antidepressant efficacy of the active ingredients, indicating that the active ingredients screened from the 5-HT1AR and 5-HTT targets can regulate the content of monoamine neurotransmitters in the brain tissue in vivo to exert antidepressant efficacy, and the in vivo pharmacodynamic experiments fully confirmed the antidepressant efficacy of the composition of the present invention.

[0017] In addition, the present invention first compounded the active ingredients targeting 5-HT1AR and 5-HTT in Yueju Pills to prepare a new composition of traditional Chinese medicine efficacy ingredients, investigated the antidepressant pharmacodynamics of the composition, and compared its antidepressant efficacy with that of the water extract and alcohol extract of Yueju Pills; it was proved that the treatment effect of the composition of three active monomers obtained based on the classical prescription Yueju Pills of the present invention is better than that of a single monomer administered alone, that is, the present invention clarified the key active ingredients that play an antidepressant role in the classical prescription Yueju Pills and their antidepressant pharmacodynamic effects, and it is expected to develop the above-mentioned efficacy ingredients into new drugs for improving and / or treating depression and anxiety disorders. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the following will briefly introduce the drawings required for the description of the specific embodiments or the prior art. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn to actual scale.

[0019] Figure 1 It shows the effect of the reserpine-induced depression model and drug intervention on the body weight of mice in the experimental examples of the present invention; Figure 2 It shows the effect of the depression model and drug intervention on the sucrose preference of mice in the experimental examples of the present invention; Figure 3 It shows the effect of the depression model and drug intervention on the immobility time of forced swimming in the experimental examples of the present invention; Figure 4 It shows the effect of the depression model and drug intervention on the immobility time of tail suspension in the experimental examples of the present invention; Figure 5 It shows the effect of different components on the contents of 5-HT, NE and DA in the serum of depressed mice in the experimental examples of the present invention; Figure 6Effects of different components on the contents of 5-HT, NE, and DA in the brain tissues of depressive mice in the experimental examples of the present invention; Figure 7 Effects of different components on Nissl bodies in the hippocampal tissues of depressive mice in the experimental examples of the present invention. Detailed implementation manners

[0020] The embodiments of the technical solution of the present invention will be described in detail below in conjunction with the embodiments. The following embodiments are only used to illustrate the technical solution of the present invention more clearly, so they are only examples and cannot be used to limit the protection scope of the present invention.

[0021] It should be noted that unless otherwise specified, the technical terms or scientific terms used in this application should have the ordinary meanings understood by those skilled in the art to which the present invention belongs.

[0022] Currently, the relevant theories about depression mainly focus on the effects on neuron cells and neuron brain networks. The protective effect of antidepressant drugs on neuron cells is also an important indicator for evaluating their activity. In addition, in vivo depressive animal models can simulate the core symptoms of human depression and induce changes in parameters such as the behavior, neurochemistry, and neuroendocrinology of animals, similar to the nervous system dysfunction of depression patients, and the use of antidepressant drugs can improve this dysfunction. In the early stage, the core antidepressant index components of Yueju Pills were screened by receptor chromatography technology as ligustilide, atractylodin, and α - cyperone. Further, using the above three components as indicators, the extraction process was optimized by orthogonal experiments, and the dry extracts obtained by the optimal process and the index components were studied for their pharmacodynamic effects.

[0023] An embodiment of the present invention provides a composition for treating depression, and the composition for treating depression includes the following components in parts by weight: Ligustilide 35 - 40 parts, atractylodin 0.5 - 1.5 parts, and α - cyperone 0.1 - 1 part.

[0024] In some embodiments, the composition for treating depression includes the following components in parts by weight: Ligustilide 37 - 39 parts, atractylodin 0.8 - 1.2 parts, and α - cyperone 0.2 - 0.5 parts.

[0025] Another embodiment of the present invention provides an application of the above - mentioned composition for treating depression in the preparation of a product for treating depression.

[0026] In one embodiment, the product is a drug or a health product.

[0027] Yet another embodiment of the present invention provides a drug for treating depression, and the drug for treating depression includes a therapeutically effective amount of the composition for treating depression.

[0028] In one embodiment, the drug for treating depression further comprises a pharmaceutically acceptable excipient.

[0029] In one embodiment, the dosage forms of the drug for treating depression include oral liquid, pills, powders, granules, tablets, capsules and injections.

[0030] Another embodiment of the present invention provides a health product for treating depression, and the health product for treating depression comprises the composition for treating depression.

[0031] In one embodiment, the health product for treating depression further comprises a food-acceptable excipient.

[0032] The technical solution of the present invention will be further described in detail by the following specific examples.

[0033] Example 1 This example is a composition for treating depression, and the composition for treating depression comprises the following components in parts by weight: 35 parts of ligustilide, 0.5 part of atractylenolide and 1 part of α - cyperone.

[0034] Example 2 This example is a composition for treating depression, and the composition for treating depression comprises the following components in parts by weight: 40 parts of ligustilide, 1.5 parts of atractylenolide and 0.1 part of α - cyperone.

[0035] Example 3 This example is a composition for treating depression, and the composition for treating depression comprises the following components in parts by weight: 38 parts of ligustilide, 1 part of atractylenolide and 0.3 part of α - cyperone.

[0036] Comparative Example 1 This comparative example is an aqueous extract of Yueju Pills, and the aqueous extract is prepared by the following method: After crushing the traditional Chinese medicine raw materials of Yueju Pills, add them to 12 times of water and extract for 1.5 h, extract three times, combine the extracts, concentrate and dry to obtain the aqueous extract.

[0037] Comparative Example 2 This comparative example is an ethanol extract of Yueju Pills, and the ethanol extract is prepared by the following method: After crushing the traditional Chinese medicine raw materials of Yueju Pills, add them to 12 times of 70% ethanol solution and extract for 1.5 h, extract three times, combine the extracts, concentrate and dry to obtain the ethanol extract.

[0038] Experimental Example A mouse depression model was constructed by continuous intraperitoneal injection of reserpine for 14 days. Behavioral experiments were used to investigate the improvement effects of the alcohol extract, water extract, and the index components ligustilide, atractylodin, and α - cyperone alone and in combination on the depressive-like behaviors of depressive mice. ELISA kits were used to determine the contents of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in the hippocampal tissue and serum of the mouse brain, and to clarify the antidepressant pharmacodynamic effects of the extract and the index component composition.

[0039] 1. Animal grouping and administration C57BL / 6J mice were randomly grouped (9 mice in each group), including a blank control group (Con), a model group (Reserpine), a fluoxetine group (Fluoxetine), an aqueous extract group, a low-dose alcohol extract group, a medium-dose alcohol extract group, a high-dose alcohol extract group, a ligustilide group, an atractylodin group, an α - cyperone group, and a monomer compound group. Except for the blank control group, the other groups were induced with a depressive model by intraperitoneal injection of reserpine, and administered by gavage for two weeks. Food was withdrawn two hours before gavage, and normal saline or reserpine was intraperitoneally injected one hour after gavage. The administration doses are shown in Table 1, and the administration doses of each composition and the medicinal material extract were calculated according to the amount of crude medicinal materials.

[0040] Table 1 Grouping and administration doses of experimental animals Serial number Grouping Drug Dosing dose 1 Normal control group (Con) Normal saline 0.2 mL / 25g 2 Model group (Reserpine) Normal saline 2.84 mg / kg 3 Positive drug group (Fluoxetine) Fluoxetine 12 mg / kg 4 Aqueous extract group (Aqueous extract) Aqueous extract 1.48g / kg 5 Low dose group (Low dose) Alcohol extract 0.5g / kg 6 Medium dose group (Medium dose) Alcohol extract 1g / kg 7 High dose group (High dose) Alcohol extract 2 g / kg 8 Ligustilide group (Ligustilide) Ligustilide 35.6 mg / kg 9 Atractylodes group (Atractylodes) Atractylodin 0.92 mg / kg 10 Cyperone group (Cyperone) Cyperone 0.3 mg / kg 11 Compound group (LCA) Ligustilide, Atractylodin, Cyperone (38:1:0.3) 36.82 mg / kg 2. Behavioral evaluation 2.1 Sucrose preference test Mice were housed individually in cages according to their groups, provided with 1 bottle of 1% sucrose solution and 1 bottle of pure water, and the sucrose consumption of mice within 6 h was measured to calculate the sucrose preference rate. Sucrose preference rate (%) = sucrose consumption / total liquid consumption × 100%.

[0041] 2.2 Forced swimming test Mice were placed in a transparent round bucket with a water depth of 35 cm (bucket height 50 cm, diameter 20 cm), water temperature: 23 - 25 °C, and forced to swim for 3 min. The immobility time (s) of mice within 3 min was recorded. When the mouse floated passively in the water and gave up struggling for more than 3 s, it was in an immobile state.

[0042] 2.3 Tail suspension test of mice The posterior 1 / 3 of the mouse tail was fixed with tape and hung on a bracket, with the head 15 cm away from the tabletop, and photographed. A white background was used for C57BL / 6J mice. After timing for 6 min, it was stopped, and the immobility time of the mouse in the last 4 min was recorded.

[0043] 3. Determination of neurotransmitter contents in mouse serum and brain tissue After the behavioral evaluation, whole blood of mice in each group was collected by enucleation. The blood was centrifuged at 5000 rpm for 10 min at 4°C, and the supernatant was transferred to a new centrifuge tube and stored in a -80°C refrigerator. The contents of 5-HT, DA, and NE in the serum were measured using an ELISA kit. The contents of 5-HT, DA, and NE in the hippocampal tissue of the mouse brain were measured using an ELISA kit. Tissue samples were homogenized in PBS at a ratio of 1:10 at low temperature. The homogenate was centrifuged at 10000 rpm for 10 min at 4°C, and the supernatant was taken for detecting the content of the sample to be measured.

[0044] 4. Determination of neurotransmitter content in mouse serum and brain tissue After blood collection, the mice were sacrificed by cervical dislocation, and the brain tissue was quickly dissected. The hippocampal region was separated and fixed in 4% paraformaldehyde (PFA, pH 7.4) for 24 hours (4°C).

[0045] Dehydration and embedding: Dehydration with gradient ethanol (70%, 80%, 90%, 95%, 100%, 1 hour each), clearing with xylene and then impregnated with paraffin wax (60°C), and paraffin embedding. Serial coronal sections with a thickness of 5 μm were cut using a paraffin microtome and attached to polylysine-coated slides. The slides were baked at 60°C for 2 hours. Nissl staining was performed according to the following steps: ① Deparaffinization and hydration: Deparaffinize with xylene I and II for 10 minutes each, and rehydrate with gradient ethanol (100%, 95%, 80%, 70%) to distilled water.

[0046] ② Staining: Immerse in 0.1% toluidine blue staining solution (pH 4.0) and stain at room temperature in the dark for 10 minutes.

[0047] ③ Differentiation: After rinsing with running water, differentiate with 70% ethanol for 5 seconds (controlled under the microscope until the background is transparent and the Nissl bodies are dark blue).

[0048] ④ Dehydration and mounting: Dehydrate with gradient ethanol (80%, 95%, 100% for 30 seconds each), clear with xylene for 5 minutes, and mount with neutral gum.

[0049] Subsequently, the CA1, CA3, and dentate gyrus regions of the hippocampus were observed under an optical microscope. The Nissl bodies were dark blue granules, and the cell nuclei were light blue.

[0050] 5. Experimental results 5.1 Effect of drug intervention on the body weight of depressive mice Figure 1During the 4-week model establishment and 3-week drug administration process in mice, compared with the normal group, the body weight of the model group showed a slow downward trend. This indicates that reserpine stimulation may cause gastrointestinal dysfunction and decreased appetite in mice, leading to slow individual growth. Compared with the model mice, the body weight of the drug administration group increased significantly, and the high-dose ethanol extract group in the drug administration group had a significant effect. Compared with the single drug administration and the combined drug administration groups, the body weight change trend of the three monomer compound LCA group was closest to that of the normal group, showing a slow upward trend, indicating that drug intervention affected the weight consumption of mice and improved anhedonia to a certain extent.

[0051] 5.2 Effects of drug intervention on the sucrose preference of depressive mice The sucrose preference test is the most commonly used evaluation index for chronic stress-induced depression models. The phenomenon of decreased sucrose preference in animal models is an indication of anhedonia, a core symptom of depression. As Figure 2 shown, compared with the normal group, the sucrose preference rate of the depressive model group mice was significantly reduced. The results indicate that long-term stress stimulation led to anhedonia in the model mice, indicating that the mice showed depressive symptoms. Compared with the model group, after drug administration, the sucrose preference rates of the mice all had varying degrees of callback. Among them, the medium-dose and high-dose ethanol extract groups and the LCA monomer compound group had a significant increase in sucrose preference rate, and the effect of the three-drug compound group was equivalent to that of the positive drug.

[0052] 5.3 Effects of drug intervention on the immobility time of depressive mice in the forced swimming test The forced swimming test reflects that animals struggle desperately to escape in this environment but are unable to do so, thus providing an inescapable oppressive environment. After a period of the experiment, the animals show a typical "immobile state", reflecting a "behavioral despair state". The experiment evaluates the degree of despair of the model mice by observing the immobility time (except for the necessary action of keeping their noses above the water surface, without any other actions), struggling time (vigorous movement of the front paws of the mice), and swimming time (regular up and down strokes of the front and hind paws) of the forced swimming of the model mice. As Figure 3 shown, compared with the control group, the swimming immobility time (i.e., the immobility time) of the model mice was longer, and the despair state was more obvious. After 4 weeks of drug administration, the mice were tested in the forced swimming test. The results showed that compared with the model group, the immobility time of the drug administration group mice was significantly reduced (p<0.05). Among them, the ethanol extract group showed a dose-dependent improvement, and the improvement effect of the LCA monomer compound group was also significant.

[0053] 5.4 Effects of drug intervention on the immobility time of depressive mice in the tail suspension test When a mouse's tail is suspended, it attempts to escape but is unable to do so, so it gives up struggling and enters a specific depressive immobile state. During the experiment, the immobility time of the animal is recorded to reflect the depressive state, and antidepressants can significantly shorten and change its state. AsFigure 4 As shown, compared with the normal group, the immobility time of the mice in the model group was significantly increased (p<0.001), indicating that reserpine-induced depressive mice presented the core symptoms of depression. Compared with the model group, the immobility time of the mice in the administration groups was significantly decreased, indicating that drug intervention could relieve depressive symptoms and the despair mood of the mice. Among the various administration groups, the anti-depressant effects of the ethanol extract group (p<0.001) and the LCA group (p<0.001) were significant.

[0054] 5.5 Changes in the Contents of 5-HT, NE and DA in the Serum of Depressive Mice after Drug Intervention In the research on depression, in addition to measuring the contents of the three neurotransmitters, serotonin (5-HT), norepinephrine (NE) and dopamine (DA) in the hippocampal tissue of mice, it is also of great scientific significance to measure these three indicators in the serum. The levels of monoamine neurotransmitters in the serum can reflect the physiological state of the whole body. Different from the concentration of neurotransmitters in local tissues (such as the hippocampus), the content in the serum can better represent the overall psychological state and biological response of the body. Measuring the contents of 5-HT, NE and DA in the serum can provide an assessment of the systematic effects of antidepressant drugs, and the changes in the neurotransmitter concentrations in the serum can be compared with those in the hippocampal tissue to further reveal the action mechanism of the active ingredients. For example, antidepressant drugs may relieve depressive symptoms by regulating the contents of these neurotransmitters in the serum and affecting the neurotransmission mechanism in the central nervous system.

[0055] As Figure 5 shown, compared with the normal group, the contents of DA, 5-HT and NE in the serum of the model group were significantly decreased (p<0.01); compared with the model mice, the contents of DA, 5-H and NE in the serum of the treatment group mice were significantly increased, and the high-dose effect was significant in the ethanol extract group; among the monomer combination and single administration groups, the combination administration of the LCA group had the strongest up-regulation of monoamine neurotransmitters, indicating that the antidepressant effects of the triple-drug compound group and the ethanol extract group were the best compared with other treatment groups.

[0056] 5.6 Effects of Drug Intervention on the Contents of 5-HT, NE and DA in the Hippocampal Region of the Mouse Brain As Figure 6As shown, compared with the normal group, the contents of DA, 5-HT, and NE in the hippocampus and cortex tissues of the model group mice were significantly decreased (p < 0.01). Monoamine neurotransmitters play an active role in the processes such as the conduction of electrochemical signals of brain neurons, the connection and regeneration of neuron cells, and jointly regulate the processes of the body's memory, mood regulation, cognition, etc. Therefore, the changes in the contents of DA, 5-HT, and NE in the brain all indicate that chronic unpredictable mild stimulation can successfully induce a mouse depression model. Compared with the model mice, the contents of DA, 5-HT, and NE in the hippocampus and cortex tissues of the treatment group mice were significantly increased. Among the extract groups, the high-dose effect of the ethanol extract was significant; among the monomer combination and single administration groups, the combination administration of the LCA group had the strongest up-regulation of monoamine neurotransmitters, indicating that the antidepressant effect of the triple-drug compound group was the best compared with other treatment groups.

[0057] 5.7 Effect of Drug Intervention on the Pathology of the Mouse Brain Hippocampal Tissue To further investigate the effect of the raw material medicine of Zirenpian on the pathological morphology of the mouse hippocampal tissue and neuron cells, Nissl staining of the hippocampal tissue pathological sections was performed. Nissl staining is used to observe the distribution and quantity of Nissl bodies in neurons and reflect the functional state of neurons. As Figure 7 shown, compared with the normal group, the Nissl bodies in the hippocampal tissue of the depression model group were significantly reduced, the neuron volume was reduced, and the distribution of Nissl bodies was sparse, indicating that the neuron function was damaged and neurons might undergo degenerative changes. Compared with the model group, the number of Nissl bodies in the positive drug group and the LCA compound group after drug treatment was significantly increased, the distribution was uniform, and the neuron volume tended to be normal, indicating that the drug could promote neuron repair and restore neuron function, suggesting that the drug might improve depression-related nerve damage through neuroprotection. Among them, the effect of the active ingredient compound group was significant compared with the single use group of active ingredients, indicating that the active ingredients could play an antidepressant role synergistically through multiple pathways.

[0058] Figures 1 - 7 Among them, Control: control group; Reserpine: reserpine model group; Fluoxetine: positive drug group; Water extract: water extract group; 70% ethanol extract low: 70% ethanol extract low-dose group; 70% ethanol extract middle: 70% ethanol extract middle-dose group; 70% ethanol extract high: 70% ethanol extract high-dose group; Ligustilide: ligustilide group; Cyperone: α-cyperone group; Atractylodin: atractylodin group; LCA: ligustilide + α-cyperone + atractylodin group; P < 0.001 vs. Con; , , .

[0059] In summary, a mouse depression model was constructed by continuously intraperitoneally injecting reserpine for 14 days. The improvement effects of the ethanol extract, water extract, and the index components ligustilide, atractylodin, and α - cyperone alone and in combination on the depressive - like behaviors of depressed mice were investigated from three aspects: behavior, neuroprotection, and monoamine system. The experimental results showed that the active ingredient composition could reduce the immobility time of depressed mice in the forced swimming test and tail suspension test, significantly improve the depressive - like behaviors of mice, and exert neuroprotective and antidepressant effects by regulating the contents of 5 - HT, DA, and NE monoamine neurotransmitters in the mouse brain tissue.

[0060] Finally, it should be noted that: the above - mentioned embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand that: they can still modify the technical solutions recorded in the foregoing embodiments, or perform equivalent replacements on some or all of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be covered within the scope of the claims and the description of the present invention.

Claims

1. A composition for treating depression, characterized in that, The composition for treating depression comprises the following components in parts by weight: 35-40 parts of ligustilide, 0.5-1.5 parts of atractylodesin and 0.1-1 parts of α-cyperone.

2. The composition for treating depression according to claim 1, wherein The composition for treating depression comprises the following components in parts by weight: 37-39 parts of ligustilide, 0.8-1.2 parts of atractylodesin and 0.2-0.5 parts of α-cyperone.

3. Use of the composition for treating depression according to claim 1 or 2 in the preparation of a product for treating depression.

4. The application according to claim 3, characterized in that, The product is a medicine or a health product.

5. A drug for treating depression, characterized in that, The drug for treating depression comprises a therapeutically effective amount of the composition for treating depression according to claim 1 or 2.

6. The drug for treating depression according to claim 5, wherein, The medicine for treating depression also includes pharmaceutically acceptable excipients.

7. The drug for treating depression according to claim 5, characterized in that, The dosage forms of the drug for treating depression include oral liquid, pills, powders, granules, tablets, capsules and injections.

8. A health product for treating depression, characterized in that, The health care product for treating depression comprises the composition for treating depression according to claim 1 or 2.

9. The health product for treating depression according to claim 8, wherein, The health care product for treating depression also includes excipients acceptable in food science.

Images